Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The targeted therapy delayed disease progression in patients with the most common type of early-stage breast cancer.
Women who received a combination of Kisqali and hormone therapy lived twice as long without their cancer getting worse.
Adding the CDK 4/6 inhibitor to hormone prolonged survival by a year.
Finding an effective alternative to multi-agent chemotherapy for patients with high-risk breast cancer is a priority.
A study in mice suggests that therapies approved for breast cancer may also combat other types, including colorectal and stomach cancer.
The FDA is warning that these drugs used to treat advanced breast cancers may cause rare but severe inflammation of the lungs.
Recently approved CDK4/6 inhibitor plus hormone therapy extends overall survival by about a third.
Precision medicine matches patients with the treatments most likely to work for them.
First approval using a new FDA process to speed up cancer drug reviews.
Ribociclib now approved for pre- and perimenopausal women with HR-positive, HER2-negative breast cancer.
New treatment options are available for those with breast cancer that has metastasized.
Indication extended to include first-line treatment of HR-positive/HER2-negative advanced or metastatic disease.
Weigh the benefits and risks of different types of therapy when considering treatment, the American Heart Association advises.
CDK4/6 inhibitor plus hormone therapy extends progression-free survival for younger women.
World’s largest breast cancer conference celebrates 40 years.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.